Cargando…

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

BACKGROUND: Given the improved convenience of oral prostacyclins, there is a shift toward their use in treating pulmonary arterial hypertension (PAH). OBJECTIVES: Our objective was to compare patient characteristics, medication adherence, healthcare resource use (HCRU), and costs among patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392967/ https://www.ncbi.nlm.nih.gov/pubmed/32144746 http://dx.doi.org/10.1007/s40801-020-00183-x

Ejemplares similares

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms
por: Mathai, Stephen C., et al.
Publicado: (2019)

Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database
por: Heresi, Gustavo A., et al.
Publicado: (2022)

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
por: Raju, Aditya, et al.
Publicado: (2021)

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
por: Mandras, Stacy, et al.
Publicado: (2021)

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
por: Correll, Christoph U., et al.
Publicado: (2017)

Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids
por: Harrington, Amanda, et al.
Publicado: (2020)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
por: Sargent, Therese, et al.
Publicado: (2020)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs
por: Schwab, Phil, et al.
Publicado: (2016)

PROSTACYCLIN IN HEALTH AND DISEASE
Publicado: (1983)

Prostacyclin: An Inflammatory Paradox
por: Stitham, Jeremiah, et al.
Publicado: (2011)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
por: Blitek, Agnieszka, et al.
Publicado: (2022)

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs
por: Saundankar, Vishal, et al.
Publicado: (2016)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
por: Kingman, Martha, et al.
Publicado: (2017)

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
por: Burger, Charles D, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Prostacyclin Regulation of Allergic Inflammation
por: Patel, Kunj, et al.
Publicado: (2022)

Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis
por: McConnell, John W., et al.
Publicado: (2020)

Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets
por: Raz, Limor, et al.
Publicado: (2014)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension
por: Wertheim, Bradley M.
Publicado: (2022)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
por: Mitchell, Jane A, et al.
Publicado: (2018)

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
por: Hopper, Rachel K., et al.
Publicado: (2018)

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
por: Hart, Stephen A., et al.
Publicado: (2018)

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Picken, Christina, et al.
Publicado: (2019)

Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer’s disease in an administrative claims database
por: Nair, Radhika, et al.
Publicado: (2018)

Prostacyclin and thromboxane in benign and malignant breast tumours.
por: Laekeman, G. M., et al.
Publicado: (1986)

Selective inhibition of prostacyclin synthase activity by rofecoxib
por: Griffoni, Cristiana, et al.
Publicado: (2007)

The pulmonary and haematological toxicity of inhaled aerosolised prostacyclin
por: van Heerden, PV, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_g1cda1adh5tehtp376oisprkjs